EMGALITY: cost and payments to doctors
What Medicare Part D paid pharmacies for EMGALITY, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Part D cost for EMGALITY formulations
Medicare reports EMGALITY under its specific formulations, which are priced separately.
- emgality pen$708per 30-day fill · 253,324 claims · Galcanezumab-Gnlm
- emgality syringe$908per 30-day fill · 21,039 claims · Galcanezumab-Gnlm
Paid to pharmacies by Part D plans and patients — not your cost, and not paid to the prescriber. Is this wrong?
Was your doctor paid by Lilly USA, LLC?
Lilly USA, LLC reported the most payments naming EMGALITY. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $13.3M
- Providers
- 66,312
- Transactions
- 316,052
- Average per transaction
- $42
The per-transaction average — $42 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 66,312 providers the average total is $200, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $13,159,909 | 99.1% |
| Eli Lilly | $97,598 | 0.7% |
| Eli Lilly Export S.A. Puerto Rico Branch | $27,736 | 0.2% |
Other products from Lilly USA, LLC
The company that reported the most payments naming EMGALITY also reports against these.